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                                                                    By 
                                                  Tatiana Victoria Piccoli 
                                                                   2017 
 
 
Introduction: Obesity-related morbidity continues to increase worldwide. Obesity is one of the 
primary conditions for the development of metabolic syndrome which is characterized by a 
combination of different components, including metabolic, physiological, and biochemical 
factors that influence the development of cardiovascular disease, diabetes mellitus type two and 
contribute to all-cause mortality. The development of metabolic abnormalities is related to 
oxidative stress which increases among obese individuals. The obese population is not 
homogenous and represented by individuals with altered and with a normal metabolic profile, 
those with the normal metabolic profile are recognized as Metabolically Healthy Obese (MHO). 
The lipid peroxidation is the main hallmark of oxidative stress and this process can be evaluated 
via the measurement of the end products such as F2 -Isoprostanes. 
Aim: The goal of this study was to investigate the relationship between metabolically healthy 
and unhealthy obesity with markers of oxidative stress (urinary F2 -Isoprostanes) and assess 
whether free radical-induced oxidative stress influences transition from metabolically healthy to 
the metabolically unhealthy group. Metabolic health was defined as blood pressure below 130/85 
mmHg, fasting blood glucose level as below 126 mg/dl and HDL-cholesterol above 40 mg/dl for 
males and above 50 mg/dl for females. 
Method: The cohort of 857 participants included Hispanic, non-Hispanic black, and non-
Hispanic white from 40 to 69 years of age and had an obesity prevalence of 29% (n=244) at 
baseline. Among this group, 11.07% (n=27) were metabolically healthy and 88.93% (n=217) 
were metabolically unhealthy based on criteria for MHO. Among the MHO group, after 5-year 
follow-up, 37% remained metabolically stable and 63% developed metabolic abnormalities and 
among the MUO group, 5.6% became metabolically healthy and 94.4% remained metabolically 
unhealthy. The association between different types of metabolic health and F2 -Isoprostanes 
species was measured using Wilcoxon rank-sum test. 
Result: The MUO status had a direct association with greater weight, Hispanic ethnicity, 
impaired glucose tolerance, decreased insulin sensitivity, and decreased fasting insulin level. No 
association was found between metabolic health status and levels of F2 -Isoprostanes at baseline 
and follow-up.  
Conclusion: The result suggests that elevated levels of F2 -Isoprostanes do not promote the 
transformation of metabolically healthy obesity into metabolically unhealthy obesity.  
Keywords: Obesity, metabolic health, metabolically healthy obesity, oxidative stress, F2 -
Isoprostanes
                                                                                 i 
 
       RELATIONSHIP BETWEEN F2 – ISOPROSTANES AND 
            ADULT METABOLICALLY HEALTHY OBESITY 
 
 
                                                       by 
                             TATIANA VICTORIA PICCOLI 
                      MD, GEORGIA STATE UNIVERSITY, GA 30303 
 
A Thesis Submitted to the Graduate Faculty of Georgia State University in Partial  
                    Fulfillment of the Requirements for the Degree 
 
 
                                                MASTER OF PUBLIC HEALTH 
 
                                                          ATLANTA, GA 
                                                                 30303 
                                           
 
                                                                                 ii 
                                                APPROVAL PAGE 
            RELATIONSHIP BETWEEN F2 -ISOPROSTANES LEVEL AND 
                  ADULT METABOLICALLY HEALTHY OBESITY 
             
 
 
                                                        by 
                                           TATIANA VICTORIA PICCOLI 
 
 
 
Approved:  
 
 
 
___Dr. Dora Il`yasova______  
Committee Chair  
 
 
 
__Dr. Emily Graybill_____  
Committee Member  
 
 
 
__12/01/2017_____________  
Date 
                                    
  
 
                                                                                 iii 
 
                                     Acknowledgements 
 
I wish to express my gratitude to my thesis chair, Dr. Il`yasova, who guided me through the 
research with patience and wise advice. My special thanks go to my committee member Dr. 
Graybill, I am very grateful for your time and recommendations. 
Additionally, I thank   my family for encouraging and supporting me throughout this research. 
 
 
 
 
 
 
 
 iv 
 
  
                                                  Author`s Statement 
    In presenting this thesis as a partial fulfillment of the requirements for an advanced degree 
from Georgia State University, I agree that the Library of the University shall make it available 
for inspection and circulation in accordance with its regulations governing materials of this type. 
I agree that permission to quote from, to copy from, or to publish this thesis may be granted by 
the author or, in his/her absence, by the professor under whose direction it was written, or in 
his/her absence, by the Associate Dean, School of Public Health. Such quoting, copying, or 
publishing must be solely for scholarly purposes and will not involve any potential financial 
gain. It is understood that any copying from or publication of this dissertation which involves 
potential financial gain will not be allowed without written permission of the author. 
 
 
                                                                                                                 Tatiana Victoria Piccoli 
                                                                                                                   (Signature of the Author)  
                                                                                       v 
                                   
                                         Notice to Borrowers 
All these deposited in the Georgia State University Library must be used in accordance with the 
stipulations described by the author in the preceding statement. 
 
The author of the thesis is: 
Tatiana Victoria Piccoli 
3555 Monticello Commons 
Peachtree Corners, GA 30092  
 
The chair of the committee for this thesis is: 
Dora Il`yasova, PhD 
Georgia State School of Public Health 
Diversion of Epidemiology & Biostatistics 
Georgia State University 
P.O. Box 3995 
Atlanta, GA 30302-3995 
 
Users of this thesis who not regularly enrolled as a student at Georgia State University are 
required to attest acceptance of the preceding stipulation by signing below. Libraries borrowing 
this thesis for the use of their patrons are required to see that each user records here the 
information requested. 
NAME OF USER ADDRESS DATE TYPE OF USE 
(EXAMINATION 
ONLY FOR 
COPYING) 
    
    
    
    
 
 
                                                                         vi 
                                                                    TABLE OF CONTENTS 
TITLE PAGE……………………………………………………………………………………. i 
APPROVAL PAGE………………………………………………………………………………ii 
ACKNOWLEDGEMENTS……………………………………………………………………. iii 
LIST OF TABLES……………………………………………………………………………...viii 
ABBREVIATIONS………………………………………………………………...……….……ix 
INTRODUCTION………………………………………………………………………………...1 
  1.1Background…………………………………………………………………………………...1 
  1.2 Purpose of study……………………………………………………………………………...3 
  1.3 Research question and hypothesis…………………………………………………………...4 
  1.4 Thesis organization………………………………………………….……...…………… ….5 
REVIEW OF THE LITERATURE…………………………………………………………....….6 
   2.1 The relationship between metabolic syndrome and oxidative stress…………………….….6 
   2.2 F2 -Isoprostanes as markers of oxidative stress ………………………………………….….7 
   2.3 MHO definition and prevalence………………………………………………………….….9 
   2.4 Relationship between inflammatory markers and markers of oxidative stress and MHO 
        status………………….………………………………………………………………….…10 
 METHODS……………………………………………………………………………………...13 
  3.1 Data source……………………………………………………………………………….…13 
  3.2 Sample selection and participant observation………………………………………………13 
                           
                                                                                       vii 
  3.3 Variable Measurement…………………………………………………………...…………14 
  3.4 The MHO phenotype definition…………………………………………………………….15 
  3.5 Statistical analysis……………………………………………………………………..........16 
                                                                
RESULTS……………………………………………………………………………………….18 
   4.1 Description of the study sample………………………………………………...................18 
   4.2 Prevalence of metabolically healthy obesity among study population……………………20 
4.3 Association between metabolically healthy obesity and F2 – Isoprostanes…………………22 
 
DISCUSSION AND CONCLUSION……………………………………………………...……25 
  5.1 Discussion of Research Question...………………………………………………………...25 
  5.2 Study strengths and limitations…………………………………………………………......27 
  5.3 Conclusion………………………………………………………………………………….28 
  
REFERENCES……………………………………………………………………………….….29 
 
 
 
 
                                                                                       viii 
 
 
                                            LIST OF TABLES 
 
Table 1: Baseline characteristics of the entire IRAS nondiabetic cohort………………………………...19 
Table 2 Metabolically Healthy and Unhealthy Obesity status at baseline and follow-up…………….….21 
Table 3 Oxidative status of MHO and MUO…………………………………………….…………….…23 
Table 4 Oxidative status at follow-up among MHO stable and MHO declined……………………….…24 
 
                                                    LIST OF FIGURES 
Figure 1. Changes in metabolic status among MHO and MUO population. 
                                             
 
 ix                                                                                       
 
                                                       ABBREVIATIONS 
 
 
BMI   Body Mass Index 
CVD                              Cardiovascular Disease 
DM                                Diabetes Mellitus 
F2 -IsoPs                     F2 - Isoprostanes 
HDL   High Density Lipoprotein 
HOMA                          Homeostasis Model Assessment  
HOMA-IR                     Homeostasis Model Assessment for Insulin Resistance 
IGT                                Impaired Glucose Tolerance  
IL                                   Interleukin 
IRAS                              Insulin Resistance and Atherosclerosis Study 
LDL                               Low-Density Lipoprotein   
MetS                              Metabolic Syndrome 
MHO   Metabolically Healthy Obesity 
MUO   Metabolically Unhealthy Obesity 
NCEP/ATPΙΙΙ           National Cholesterol Education Program Adult Treatment Panel ΙΙΙ 
NHANS                      National Health and Nutrition Examination Survey 
ox-LDL                      Oxidized Low-Density Lipoprotein  
P-value                       Probability value (observed significant level) 
ROS                               Reactive Oxygen Species 
TNF- α                            Tumor necrosis factor alfa 
 
 
 
 
1 
 
                                                          CHAPTER Ι 
                                                      INTRODUCTION 
 
1.1 Background 
         Increase in obesity prevalence worldwide contributes to the growth of obesity-related 
morbidity (Landsberg et al., 2013). The study conducted by Finucane et al. (2011) investigated 
the obesity increase in 199 countries from 1980 to 2008. The result of the study demonstrated 
that 502 million adults had BMI above or equal to 30 kg/m 2 that allowed qualifying them as 
obese. Obesity is one of the primary conditions for the development of metabolic syndrome 
(Montague and O'rahilly, 2000, Furukawa et al., 2017), which is characterized by a combination 
of different components, including metabolic, physiological, and biochemical factors that 
influence the development of cardiovascular disease, diabetes mellitus type two and contribute to 
all-cause mortality (Kaur, 2014). The mechanism of development of metabolic syndrome is 
closely related to systemic oxidative stress (Keaney et al., 2003), which is more prominent 
among the obese population due to the tendency of adipose tissue to produce reactive oxygen 
species (ROS) in higher amount compared with other tissues (Furukawa et al., 2017). On one 
hand, the obesity has an association with diabetes, hypertension, cancer and other numerous 
health conditions, hence contributing to increase of the healthcare expenditure (Allen, Thorpe, 
and Joski,2015). On another hand, the health programs targeting this global health problem 
showed very little success on a population level (Ng et.al., 2014). Additionally, the expenditure 
of community-based programs targeting obesity can vary due to the kind of approach and variety 
of interventions included in this program.  Finkelstein et al. (2008) showed that, on average,
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medical spending on obese individual $1,429 higher per year compared with a person of normal 
weight 
        Nevertheless, the obese population is heterogeneous and consists of individuals with a 
variety of degree of obesity and metabolic abnormalities (Blüher,2014). Considering variability 
of individuals representing the obese population, it would be beneficial to allocate this 
population into groups according to their degree of metabolic abnormalities for being able to 
address their needs more specifically and cost-efficiently. Among the obese population, we can 
identify a group of individuals that do not have obesity-related comorbidities and do not 
demonstrate any evidence of metabolic abnormalities, including insulin sensitivity and lipid 
profile in the normal range and normal blood pressure, based on these criteria this subdivision is 
identified as metabolically healthy obese (MHO) (Primeau et al., 2011). However, it is not clear 
how healthy this group is and whether it progresses to metabolically unhealthy obesity (MUO). 
The large body of literature supports the evidence about beneficial inflammation profile of MHO 
individuals compared with metabolically unhealthy obese (MUO) population. Moreover, 
comparing MHO population with the non-obese group, no association was found between the 
MHO status and cardiovascular disease (CVD) prevalence and all-cause mortality (Calori et 
al.,2011, Hamer and Stamatakis, 2012, Iacobellis et al.,2007, Karelis et al., 2005). However, 
some researchers provide the evidence about the temporary condition of metabolic health among 
obese individuals who with time will develop metabolic abnormalities (Appleton et al., 2013). 
Additionally, some researchers found that although MHO population has not demonstrated any 
signs of metabolic abnormalities, their metabolic profile was inferior to the profile of non-obese 
individuals, including a lower level of HDL-cholesterol and higher non-HDL cholesterol (Manu 
et al., 2012). Furthermore, some studies demonstrated that this population undergoes subclinical 
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changes, such as early atherosclerosis (Oflaz et al.,2003). Based on contradicting results of 
several studies Denis and Obin (2013) suggested that MHO group should be viewed as a “cluster 
of traits” instead of as a category that can have a prognostic importance. Similarly, Plourde and 
Korelis (2014) questioned whether MHO is a permanent status or just a stage in the development 
of metabolic abnormalities accompanying obesity. Reviewing several longitudinal studies with 
controversial results, the authors concluded that future metabolic health of individuals belonging 
to MHO population cannot be guaranteed.   
          A level of influence of systemic oxidative stress in developing metabolic abnormalities 
among metabolically healthy obese can be assessed by measuring the association between the 
products of oxidative stress and MHO status. The lipid peroxidation is the main hallmark of 
oxidative stress, where free radicals activate the process. The degree of lipid peroxidation can be 
evaluated via the measurement of the end products of this process (Milne et al., 2005). The group 
of the secondary end products of lipid peroxidation includes prostaglandin-like products called 
F2 – Isoprostanes (F2 -IsoPs) that represent the result of peroxidation of arachidonic acid induced 
by free radicals. The F2 -Isoprostanes species demonstrated a higher accuracy of the reflection of 
oxidative stress compared to other markers (Fam and Morrow, 2003). 
1.2 Purpose of the study  
            The rich body of literature investigated the role of different lifestyle factors, such as 
physical activity and diet on metabolic health (Phillips et al., 2013), the association between a 
proinflammatory profile and metabolic status (Plourde and Korelis,2014), and F2 -Isoprostanes as 
the markers of oxidative status (Morrow et al., 1995, Il`yasova et al., 2015). To the best of our 
knowledge, only one study, with a cross-sectional design, has been conducted to analyze the 
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association between different types of metabolic status of the overweight/obese population and 
the 8-epi-prostaglandins F2α, that represent the most common form of F2 -Isoprostanes (Kim et 
al., 2013). But no study has been conducted to evaluate the association between four types of F2 
– Isoprostanes and metabolically healthy obesity (MHO).  
     The purpose of this study was to explore the relationship between the different metabolic 
profiles and level of four different forms of F2 - Isoprostanes among the obese population, in a 
prospective cohort, and to determine whether the level of F2 -Isoprostanes can predict the 
transformation from MHO into MUO. Additionally, to determine what health characteristics 
determining metabolic health have a correlation with the level of F2 -Isoprostanes.  
 
1.3 Research question and hypothesis  
      1). Is there a cross-sectional association between concentration of F2-Isoprostanes and 
Metabolically Unhealthy Obesity (MUO) status? 
Compared to Metabolically Unhealthy Obese (MUO) population the MHO population 
shows a lower level of F2 -Isoprostanes 
      2). Is there an association between level of F2 -Isoprostanes and transition from MHO to 
MUO?                                                
Compared to MHO population that continue to stay MHO after 5 years of follow-up the 
MHO population that progresses into MUO has a higher level of F2 -Isoprostanes. 
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1.4 Thesis Organization 
         This thesis is presented in five chapters. The first chapter contains an introduction with the 
description of the background information, purpose of the study, research questions and 
hypothesis. The literature review is presented in chapter two. The methods, sample, and 
measures described in chapter three. Next chapter presents the result of the study. The last 
chapter contents discussion, recommendations, strength and limitation of the study. 
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                                                       CHAPTER ΙΙ 
                                              LITERATURE REVIEW 
2.1 The relationship between metabolic syndrome and oxidative stress 
         The increasing prevalence of metabolic syndrome (MetS) worldwide and the related 
increase in CVD and diabetes type two prevalence became one of the main concerns of public 
health (Ceriello and Motz, 2004, Sjorgen, 2005). The changes in lifestyle, such as overnutrition 
and lack of physical activity, contribute to the development of the bundle of pathophysiological 
divergences that incorporate dyslipidemia, insulin resistance, high blood pressure, and impaired 
glucose tolerance. Additionally, all these changes are frequently associated with obesity (Eckel et 
al., 2005, Kahn et al.,2006, Xu et al.,2012). The mechanism of the development of metabolic 
syndrome is not completely understood (Bonomini et al., 2015). Even though obesity is one of 
the main drivers of MetS, there is a population of normal weight individuals with MetS 
(Ruderman et al., 1998, St-Onge et al., 2004). The study conducted by Park et al. (2003) 
evaluated the prevalence of metabolic syndrome among a multiethnic sample from the third 
National Health and Nutrition Examination Survey (NHANS) demonstrating that 4.6% of normal 
weight participants had metabolic syndrome with obese individuals showing a higher prevalence 
of metabolic syndrome compared to non-obese (59.6% vs 4.6%.) Throughout the last years, 
“metabolically triggered inflammation” is recognized as a characteristic of obesity and a 
contributor to the development of metabolic syndrome (Hotamisligil, 2006). Similarly, the 
development of metabolic abnormalities that lead to dyslipidemia (Zelzer et al.,2011),                                                            
hypertension (Russo et al., 1998) and diabetes ((Keaney et al.,2003) is influenced by oxidative 
stress. Oxidative stress is considered a condition with a disproportion between reactive oxygen
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species (ROS) and capacity of antioxidants (Roberts and Sindhu, 2009) that results in increased 
lipid peroxidation and damage to cellular structures (Yakes and Van Houten, 1997). The 
evidence about the relationship of metabolic syndrome and oxidative stress is supported by the 
decreased level of antioxidants among patients with MetS (Armutcu et al., 2008). Palmieri and 
Sblendorio 2006, showed the increased frequency of metabolic syndrome among 
postmenopausal women and thought to be due to the elevated free fatty acids (FFA) level and 
subsequent oxidative stress. Numerous studies demonstrated a positive association between 
metabolic status and markers of oxidative stress (Guilder et al., 2006, Hansel et al., 2004, 
Holvoet et al.,2004), confirming the hypothesis about a vital role of oxidative stress in the 
development of metabolic syndrome. 
2.2 F2 -Isoprostanes as markers of oxidative stress 
            Throughout the last decades, the group of prostaglandin-like structures called F2 – 
Isoprostanes became a well-recognized tool for assessing oxidative status (Basu, 2008, Il'yasova 
et al.,2012). Roberts and Milne (2009) stated that due to the stability of molecules of F2 - 
Isoprostanes, their level the most accurately reflects the grade of oxidative injury in vivo. The 
circulation of free F2 – Isoprostanes in plasma and excretion with the urine gives an opportunity 
to evaluate oxidative status in humans and animals (Li et al.,1999, Roberts and Morrow,2000). 
Moreover, the quantification of the level of F2 – Isoprostanes in body fluids that reflect normal 
oxidative status allowed identifying the condition when lipid peroxidation exceeds the capacity 
of antioxidant defense and is recognized as oxidative stress (Milne et al.,2005). Analyzing the 
result of the study investigating the relationship between the level of F2 - Isoprostanes and 
hypercholesterolemia, Milne et al. (2005) concluded that this positive association is likely due to 
oxidative stress among this population. Similarly, the elevated level of F2 – Isoprostanes was 
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found among patients with diabetes. Comparing groups of patients with and without diabetes, 
Gopaul et al. (1995) showed that the group with diabetes had 3.3- fold elevation in F2 – 
Isoprostanes level compared to the nondiabetic group. Another confirmation about the elevation 
of F2 – Isoprostanes during oxidative stress was provided by Morrow et al. (1995) showing the 
increased level of F2 – Isoprostanes among smokers compared to nonsmokers. The authors 
concluded that the negative effect of smoking can be attributed to oxidative injury caused by 
toxic products inhaled during the smoking process. An article by Milne et al. (2015) provided an 
overview in the field of F2 – Isoprostanes research for 25 years since the discovery of F2 – 
Isoprostanes by Morrow and Roberts. Since that time numerous studies have been conducted 
with the purpose of exploring the possibilities of using these compounds as biomarkers for 
illnesses. Several studies investigated the association between toxic agents causing oxidative 
damage and level of F2 – Isoprostanes as markers of this injury and reported a positive 
relationship between these variables (Il'yasova et al.,2010, Kadiiska et al., 2005). Another study 
examining the levels of F2 – Isoprostanes among the population of Inuit, showed an elevated 
level of these markers among the participants with metabolic syndrome compared to individuals 
with normal metabolic health (Alkazemi et al.,2012). A similar result was presented by the study 
conducted by Black et al. 2016, showing a positive association between F2 – Isoprostanes and all 
constituents of metabolic syndrome including systolic blood pressure, triglycerides level, waist 
circumference, and LDL- level, but also surprisingly showing a positive correlation with HDL. 
Although the research conducted by Melton et al., (2017), did not show any association between 
F2 – Isoprostanes index and hypertension. The authors concluded that free radical-induced 
oxidative stress did not play an important role in the development of hypertension.  
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2.3 MHO definition and prevalence  
       Despite the longtime existing knowledge of such phenomenon as metabolically healthy 
obesity (MHO), there is still no common adopted definition of MHO. Similar to variability in the 
definition of metabolic syndrome (Borch-Johnsen, 2007) variety of sets of criteria are used to 
define MHO. Presently, about 15 different sets of criteria have been used to describe MHO status 
(Plourde and Karelis, 2013).  Many researchers agree to use lipid profile, glycemic status, and 
blood pressure as criteria to define metabolic health among the obese population, others claim 
that it is important to use the additional components (Velho et al., 2010). Based on different 
criteria, the prevalence of MHO among obese individuals varied from 6.8% to 36.6% (Phillips et 
al., 2013). Analyzing the results of several studies, Phillips (2013) stressed attention to MHO 
prevalence inconsistency across the studies that partially can be attributed to geographic, ethnic, 
age, and sample size differences, but mainly due to differences in criteria used for the definition 
of MHO. Furthermore, an even more significant variability of MHO prevalence from 6% to 75% 
in different studies was presented by Rey-Lopez et al. (2014).  Although most studies 
incorporated the basic criteria of metabolic health such as the level of HDL-cholesterol, results 
of blood pressure measurements, blood glucose level, and triglycerides, also many of them used 
additional criteria, such as waist circumference, level of LDL-cholesterol, and others. The usage 
of these extra criteria can explain a variability in MHO prevalence (Rey-Lopez et al., 2014). 
Similarly, the result of the study conducted by Velho et al. (2010) showed that MHO prevalence 
varied from 3.3% to 32.1% among men and from 11.4% to 43.3% among women, depends on 
criteria used. This study investigated the prevalence of MHO among the same group of 
participants by using six different sets of criteria and allowed to demonstrate that a variability in 
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MHO prevalence was based on differences in used criteria.  However, despite the utilization of a 
variety of criteria for MHO definition, many studies found a positive association between sex 
and MHO status, with women showing a higher prevalence of MHO, and age, with younger age 
being healthier (Rey-Lopez et al., 2014). 
2.4 Relationship between inflammatory markers and markers of oxidative stress and MHO 
status. 
     Reviewing several studies Vincent and Taylor (2006) admitted the positive relationship 
between obesity and oxidative stress. Although the association of obesity and F2 - Isoprostanes as 
markers of oxidative stress has been demonstrated in several studies (Il`yasova et al.,2005, 
Keaney et al., 2003, Stojiljkovic et al.,2002, Wu et al. 2009), literature on evaluation of oxidative 
stress and specifically level of F2 - Isoprostanes among MHO population is limited. The results 
of prospective cohort study examining the relationship between MHO, MUO, markers of 
oxidative stress and development of cognitive impairment was presented by Farah et al. (2016). 
Researchers found the positive association between oxidative stress, mild cognitive deterioration 
and MUO status. This study did not use F2 – Isoprostanes as markers of oxidative stress. Another 
study conducted by Bañuls et al. (2017) investigated the relationship between markers of 
oxidative stress, endoplasmic reticulum stress and status of metabolic health among the obese 
population. The result of the study showed a higher level of proinflammatory cytokines, such as 
IL-6 among MUO compared to MHO. Moreover, the production of ROS was lower among 
MHO compared to MUO, demonstrating a more significant level of oxidative stress among 
MUO population. Similarly, this study did not utilize F2 – Isoprostanes as markers of oxidative 
injury.  The result of the study investigating the relationship between markers of oxidative stress 
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and status of metabolic health among postmenopausal women was presented by Kim et al. 
(2013). The group of 1846 individuals was divided into four groups according to their body mass 
index (BMI), and metabolic health status. Participants with BMI≥25 kg/m2 considered to be 
overweight/obese and were divided into two groups based on the criteria for metabolic health 
defined by the modified National Cholesterol Education Program Adult Treatment Panel ΙΙΙ 
(NCEP/ATPΙΙΙ). All participants with BMI<25 kg/m2 were also divided into two groups with 
MetS and without MetS. For evaluating oxidative stress, researchers measured the level of 
inflammatory markers such as circulating oxidized LDL (ox-LDL) and 8-epi-prostaglandins F2α 
(8-epi-PGF2α). The design of the study was cross-sectional, allowing to see the association 
between the variables but not the causation. The result of the study demonstrated that 
participants from overweight/obese group had less favorable metabolic profile compared to the 
normal weight group regardless of their metabolic health. Additionally, comparing subgroups 
with MetS and without of MetS, investigators saw a better metabolic profile among individuals 
without MetS regardless of their BMI. Overweight/obese individuals without MetS demonstrated 
a higher level of ox-LDL compared to the normal weight group without MetS, but lower than 
among the group with MetS. The level of 8-epi-PRG2α was higher among participants with MetS 
compared to women without MetS. Researchers concluded that postmenopausal women with 
MetS with normal weight demonstrated a higher level of oxidative stress compared to 
overweight/obese with normal metabolic health. Additionally, between the markers of oxidative 
stress, no association was found that draw a conclusion about representation by these markers 
different stages of oxidative changes. The result of this study contradicts the result of the 
research conducted by Sjorgen et al. (2005). In this cross-sectional study, the sample was divided 
into three groups according to their metabolic risk factors, based on NCEP/ATPΙΙΙ panel. One 
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group was presented by individuals without any risk factors for MetS, another with 1-2 risk 
factors, and the third group by participants with MetS.  Examining the relationship between 
markers of oxidative stress, such as ox-LDL and 8-iso-PGF2α with the metabolic status of 
otherwise healthy men (n=289), researchers did not find any association between these variables. 
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                                                   CHAPTER ΙΙΙ 
                                               METHODOLOGY  
3.1 Data source 
       The collected data from Insulin Resistance Atherosclerosis Study (IRAS) became the source 
of our secondary data analysis. This study was the first epidemiological study intended to 
evaluate the association between constituents of insulin resistance syndrome, CVD, and other 
risk factors (Wagenknecht et al., 1995). The study began in 1992 with a follow-up period of 
approximately five years and was approved by the Institutional Review Board of Wake Forest 
University School of Medicine (Melton at al., 2017) 
3.2 Sample selection and participant observation 
        The study aimed to observe multiethnic cohort that was achieved with the recruitment of 
1626 participants representing the Hispanic population (n=548), Non-Hispanic black (n=464), 
and Non-Hispanic white (n=614). Female population represented 56% of the sample. The 
participants were from 40 to 69 years of age. Aiming to have equal representation of individuals 
with a different level of glucose tolerance, the study oversampled nondiabetic individuals with an 
elevated fasting plasma glucose level and those who were previously identified as having 
impaired glucose tolerance (IGT). The participants were recruited at four clinical centers located 
in Los Angeles, California; Oakland, California; San Luis Valley, Colorado; and San Antonio, 
Texas (Wagenknecht et al., 1995). Each participant gave written informed consent. The complete  
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examination of each participant at the baseline was achieved during two visits, each lasted 
approximately four hours, with the variation of the interval between the appointments from one 
to thirty days. During these appointments, the participants were evaluated for glucose tolerance 
using a 75g glucose load and insulin resistance using an insulin injection. CVD and peripheral 
vascular disease were assessed using an interview, performed in their preferred language, and 
noninvasive testing, such as blood pressure measurement, electrocardiography, and 
ultrasonography. Additionally, the participants completed a questionnaire self-reporting their 
race/ethnicity, smoking, alcohol intake, physical activity, and nutrient intake. Anthropometric 
measurements were performed by trained medical personnel. Moreover, for examining F2 – 
Isoprostanes level 901 enrollees provided a urine sample at the baseline. The examination of the 
participants began in October 1992 and was completed in April 1994. After approximately five 
years of the follow-up period, in 1997-1998, the study`s participants were examined again 
according to the protocol of the study. The participants free of diabetes mellitus (DM) type two 
at the baseline were included in the study analysis, that reduced the sample to 1125 participants, 
among those, 20 % were lost to follow-up.  
3.3 Variable Measurement 
       World Health Organization criteria (WHO,1999) provided guidance for assessing glucose 
tolerance. A blood sample was taken before administering 75g of glucose and two hours after. 
Insulin resistance was measured after an injection of 50% glucose solution (0.3 g/kg) in 20 
minutes followed by an injection of insulin (0.03 U/kg). During a three hours’ period, blood was 
collected 12 times through another intravenous line and was evaluated for the concentration of                                                                      
glucose and insulin. The blood sample was drawn after fasting for 12 hours to assess the level of
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lipids, fasting blood glucose, and components of the biochemical profile. At the baseline 
examination, morning urine samples were collected and kept at – 70o C until the analysis. A total 
number of 901 samples of urine were collected, among those 857 samples were satisfyingly 
measured for F2 – Isoprostanes concentration. The measurement of F2 – Isoprostanes was 
performed utilizing liquid chromatography/tandem mass spectrometry, the result was calibrated 
according to the urinary concentration of creatinine. Four different F2 – Isoprostanes isomers 
were measured including iPF(2a)-ΙΙΙ, 2,3-dinor-iPF(2a)-ΙΙΙ, iPF(2a)-lV, 8,12-iso-iPF(2a)-lV. The 
F2 -Isopostanes index was created based on the result for four F2 – Isoprostanes isomers and 
allowed to rank participants based on this calculation [(X1i – M1)/SD1 +(X2i -M2)/SD2 +(X3i -
M3)/SD3 +(X4i -M4)/SD4)/4. In this formula, “i” is a code for a participant, X1-4 represent values of 
four F2 – Isoprostanes isomers, M1-4 mean of these four isomers, and SD1-4 standard deviation 
values. The body mass index, as a measurement of general adiposity, was calculated as a 
relationship between body mass in kilograms divided by height in square meters.  
3.4 The MHO phenotype definition 
       We identified two different groups of MHO based on two different definitions of this 
phenomenon. One of the most commonly used definitions of MHO status included the absence 
of diabetes, hypertension, and dyslipidemia (Muñoz-Garach et al.,2016). We used 126 mg/dl of 
fasting blood glucose level as a cut-off for diabetes.  Enrollees with fasting plasma glucose level 
<126 mg/dl were considered nondiabetic. Individuals with systolic blood pressure equal or below 
130 mmHg and diastolic blood pressure equal or below 85 mmHg and not taking blood pressure 
lowering medication were considered normotensive. Lipid profile was represented by the level of 
HDL-cholesterol, which was considered of normal value if its level was above or equal to 
40mg/dl among males and above or equal 50mg/dl among females. All participants who met the 
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criteria for the first definition were united in the group named MHO1. Another definition of 
MHO status was based on modified criteria suggested by Wildman et al. (2008). This group 
included individuals with normotensive status (BP ≤130/85 mmHg) who did not undergo 
antihypertensive treatment. The absence of diabetes with fasting blood glucose level ≤ 100mg/dl 
was another criterion. Moreover, for being included in this MHO group additional criteria had to 
be met, such as homeostasis model assessment of insulin resistance (HOMA-IR) ≤ 5.1 and 
triglycerides HDL-cholesterol ratio ≤ 1.65 for male and ≤1.32 for female. This group was named 
MHO2. 
3.5 Statistical analysis 
        Statistical analysis was performed using SAS statistical software (version 9.4: SAS 
Institute, Cary, NC). A total number of 857 nondiabetic participants were included in this 
analysis at the baseline. The descriptive statistical analysis was applied to the baseline sample.  
The individuals with BMI ≥ 30kg/m2 were selected and the final sample was represented by 244 
participants. At the follow-up visit, this sample reduced to 241 participants. The association 
between categorical variables, including a crude association between age category, sex, ethnicity 
and MHO1 and MHO2 groups, was measured using chi-square test. Univariate analysis was 
perfumed to identify a median and interquartile range for continuous variables. We used 
Wilcoxon rank-sum test to evaluate how different were continuous variables, including F2 – 
Isoprostanes levels, between groups with MHO and MUO. We analyzed the differences between                                                                     
MHO and MUO groups at the baseline and at the follow-up appointment. Additionally, at the 
follow-up, we analyzed metabolic changes including how many MHO participants remained 
stable after five years of follow-up and how many demonstrated a decline in their metabolic 
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health and evaluated their association with oxidative stress markers among the participants. A p-
value was considered statistically significant if it was less than 0.05 
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CHAPTER ΙV 
                                                  RESULTS 
                                                     
4.1 Description of the study sample 
       The study population at the baseline included a slightly higher number of females (58%) 
compared to males (42%). Racial/ethnic diversity was represented by Hispanic (32%), Non-
Hispanic black (28%) and Non-Hispanic white (40%). Among the age categories the highest 
representation was in the group from 50 to 59 years of age (36%), groups from 40 to 49 years of 
age and 60 to 69 years of age were represented equally 32% each. Almost half of the baseline 
population never smoked (46%), former smokers represented 40% of the population, and current 
smokers 14 %. Among the baseline population, 40% had hypertension and 60 % did not have 
increased blood pressure and did not take hypertensive medication. Approximately two-thirds of 
the baseline population (67.5%) belonged to the group with normal glucose tolerance and one-
third (32.5%) had impaired glucose tolerance. The baseline sample did not include participants 
with diabetes. Prevalence of obesity (BMI≥30kg/m2) was 29%, (n=244) of the baseline 
population.  
 
 
 
 
 
 
 
 19   
 
                                                                    
Table 1. Baseline characteristics of the entire IRAS nondiabetic cohort. 
Continuous variables N (missing values) Means (SD) 
Age (years) 857 (0) 54.6 (8.315) 
BMI (kg/m2 ) 855 (2) 28.5 (5.655) 
Fasting Glucose (mg/dl) 857 (0) 98.6 (11.3) 
Insulin sensitivity 
 (SI, x10-4minutes-1/µUml) 
795 (62) 2.20 (2.05) 
 Acute Insulin Response (microU/ml) 834 (23) 486.8 (494.3) 
iPF(2a)-ΙΙΙ (ng/mg CN) 853 (4) 0.249 (0.194) 
2,3-dinor-iPF(2a)-ΙΙΙ (ng/mg CN) 853 (4) 4.35 (2.10) 
iPF(2a)-lV (ng/mg CN) 853 (4) 6.49 (4.16) 
8,12-iso-iPF(2a)-lV  (ng/mg CN) 853 (4) 4.15 (2.87) 
F2 -IsoP Index* 853 (4) -0.001 (0.821) 
2-hour Glucose (mg/dl) 857 (0) 124.3 (33.5) 
HDL (mg/dl) 854 (3) 47.11 (15.17) 
Triglycerides (mg/dl) 853 (4) 130.7 (81.37) 
Fasting Insulin (uU/ml) 856 (1) 15.69 (15.13) 
Categorical variables N (missing values) Percent 
Gender 855 (2) 100 
            Males 363 42.46 
            Females 492 57.54 
Race/ethnicity 855 (2) 100 
           Hispanic 276 32.28 
            Non-Hispanic black 237 27.72 
           Non-Hispanic white 342 40.0 
Smoking status 855 (2) 100 
               Never smoked 397 46.43 
               Former smoker 338 39.53 
               Current smoker 120 14.04 
Hypertension 855 (2) 100 
               Yes 339 39.65 
               No 516 60.35 
Obesity 244 (0) 100 
        MUO 217 88.93 
        MHO 27  11.07  
 Glucose tolerance status 855 (2) 100 
                 NGT 577 67.49 
                 IGT 278 32.51 
 
• Index* -mean of 4 standardized F2-Isoprostanes. 
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  4.2 Prevalence of metabolically healthy obesity among study population 
  Among the obese population, 27 individuals (11.07%) met criteria for MHO1 and 3 participants 
(1.23%) were recognized as metabolically healthy based on the criteria for MHO2 definition. All 
participants who met criteria for MHO2 definition also met the criteria for MHO1 definition. At 
follow-up, the sample from the obese population decreased (n=241) and included 22 participants 
(9.1%) belonging to the metabolically healthy (MH) group and 219 participants (90.9%) were 
metabolically unhealthy (MU). These 22 MHO individuals met the criteria for MHO1 definition. 
Additionally, 10 participants (4.1%) met criteria for MHO2 definition at follow-up. All 
participants who can be considered MHO2 also met the criteria for MHO1.  Age category and 
sex did not show a statistically significant association with MHO status at baseline and follow-
up. Smoking status did not demonstrate an association with MHO status at baseline, showing an 
equal prevalence of MHO among former smokers and participant who never smoked (44.4% 
each). At follow-up, this association increased with 45.4% of individuals who never smoked 
representing the MHO group of which 36.4% were former smokers, current smokers represented 
less than 20% of MHO population on both visits (P=.06). At baseline participants belonging to 
the Hispanic group demonstrated the lowest prevalence of MHO (14.8%) and the highest 
prevalence of MUO (37.3%) compared to two other racial/ethnic groups (P=.05). Although this 
trend continued to the follow-up, it became less statistically significant (P=.08). As anticipated, 
the MHO status was associated with glucose tolerance status, insulin sensitivity, and fasting 
insulin. Although an association between MHO status and BMI was not statistically significant at 
baseline, at follow-up there was a statistically significant association demonstrating higher 
median BMI among MUO compared to MHO (P=.01) (Table 2). 
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Table 2 Metabolically Healthy and Unhealthy Obesity status at baseline and follow-up. 
 Baseline N= 244 (percent) p-value Follow-up N=241 (percent)  p-value 
 Categorical Variable* 
 
MHO 
N=27 
MUO 
N=217 
 MH 
N=22 
MU 
N=219 
 
Age    0.07   0.5 
        40-49 10 (37.04) 71 (32.72)  9 (40.91) 70 (31.96)  
         50-59 13 (48.15) 69 (31.80)  8 (36.36) 74 (33.79)  
         60-69 4 (14.81) 77 (35.48)  5 (22.73) 75 (34.25)  
Gender   0.9   0.7 
        Male 9 (33.33) 70 (32.26)  8 (36.36) 71 (32.42)  
        Female 18 (66.67) 147 (67.64)  14 (63.64) 148 (67.58)  
Ethnicity   0.05   0.08 
       Hispanic 4 (14.81) 81 (37.33)  3 (13.64) 81 (36.99)  
       Non-Hispanic black 12 (44.44) 60 (27.65)  8 (36.36) 64 (29.22)  
      Non-Hispanic white 11 (40.74) 76 (35.02)  11 (50.00) 74 (33.79)  
Smoking status 
 
  0.76   0.06 
          Never    smoked 12 
(44.4) 
111 
(51.2) 
 10 (45.4) 109 (50.7)  
       Former smoker 12 
(44.4) 
81 
(37.3) 
 8 (36.4) 95 (44.2)  
        Current smoker 3 
(11.2) 
25 
(11.5) 
 4 (18.2) 11 (5.1)  
Hypertension 
N, % 
  N/A   N/A 
           Yes 0 143 
(65.90) 
 0 163 (74.43)  
            No 27 
(100.00) 
74 
(34.10) 
 22 (100.00) 56 (25.57)  
Glucose tolerance 
status 
N, % 
  0.01   < .001 
          NGT 20 
(74.06) 
103 
(47.47) 
 19 (86.36) 82 (37.44)  
          IGT 7 
(25.94) 
114 
(52.53) 
 2 (9.09) 68 (31.05)  
Type 2 diabetes N/A N/A  1 (4.55) 69 (31.51)  
Continuous Variable Median ± 
IQR 
Median ± 
IQR 
 Median ± IQR Median ± 
IQR 
 
BMI 
Kg/m2  
33.08 
(31.23-
36.33) 
34.27 
(31.89- 
37.705) 
0.126 30.29 
(29.02- 36.00) 
 35.45 
(31.99- 38.53) 
0.01 
Fasting Glucose 
(mg/dl) 
98.0 
(91-104) 
102.0 
(95-111) 
N/A 96.0 
(90.0-104.5) 
105.5 
(95.5-121.5) 
N/A 
Insulin sensitivity 1.54  0.85 <.001 1.10 0.51 < .001 
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(SI, x10-4minutes-1/µUml) 
 
(1.28-2.62)  (0.370- 
1.54) 
(0.96-2.50) (0.0-0.98) 
Acute Insulin response 
(microU/ml) 
565.0 
(161.6- 
710.8) 
417.6 
(137.4-
790.4) 
0.552 428.5 
(354.8- 735.8) 
346.2 
(98.00- 847.1) 
0.19 
2-hour Glucose 
(mg/dl) 
116 
(95-141) 
142  
(120-167) 
<.001 108.0 
(89.0-122.5) 
155.5 
(124.5- 213.7) 
< .001 
HDL (mg/dl) 55.0 
 (51.0-57.0) 
40.0  
(33.0-46.5) 
N/A 58.5  
(51.0-65.0) 
43.0 
(35.0-51.0) 
N/A 
Triglycerides 
(mg/dl) 
104.0  
(74.0-183.0) 
139.0  
(90.0-182.0) 
N/A 76.0 
(59.0-127.0) 
124.0 
(86.0-179.0) 
N/A 
Fasting Insulin (uU/ml) 14.0 
 (11.0-21.0) 
19.0  
(14.0-26.0) 
0.005 15.0 
(11.0-18.0) 
23.0 
(16.0-33.0) 
< .001 
• Variables value correspond to each time point. All categorical variables reported in N, %, p-value 
for categorical variables assessed using Chi-square.  All continuous variables reported in median 
± IQR assessed using univariate test, p-value for continuous variables assessed using Wilcoxon 
test. 
 
4.3 Association between metabolically healthy obesity and F2 – Isoprostanes 
 
     Each individual F2 – Isoprostanes isomer demonstrated the variability of distribution. 
Examined association between MHO status and level of each isomer of F2 – Isoprostanes was not 
statistically significant. Majority of F2- Isoprostanes species demonstrated an inverse association 
with MHO status, such iPF (2a)-ΙΙΙ, 2,3-dinor – iPF (2a)-ΙΙΙ, 8,12-iso-iPF, and F2 -Isoprostanes 
Index all were slightly higher among MUO compared with MHO group at baseline. Although 
iPF(2a)-lV had a direct association with MHO status being higher among MHO (median=7.53 
ng/mg) compared to MUO (median= 5.93 ng/mg). None of the associations were statistically 
significant. Assessment of the association between levels of F2 – Isoprostanes and MHO status 
on follow-up demonstrated an increase in the number of F2 – Isoprostanes having direct 
associations with MHO status with only iPF(2a)-lll being slightly higher among MUO (0.214 
ng/mg) compared with MHO (0.212 ng/mg).
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The associations between F2 – Isoprostanes isomers and MHO status on follow-up were not 
statistically significant (Table 3). 
Table 3 Oxidative status of MHO and MUO 
 Baseline N=244 (median, 
IQR) 
p-value Follow-up N=241 (Median, 
IQR) 
p-value 
variable MHO N=27 MUO N=217  MH N=22 MU N=219  
     iPF(2a)-lll 
 (ng/mg) 
0.178 
(0.148- 0.418) 
0.215 
(0.127- 0.330) 
0.795 0.212 
(0.158- 0.336) 
0.214 
(0.127- 0.330) 
0.66 
 
     2,3-dinor-
iPF(2a)-lll 
 (ng/mg) 
4.322 
(2.944- 6.689) 
4.687 
(2.954- 6.763) 
0.659 4.804 
(3.223- 7.435) 
4.670 
(2.930- 6.689) 
0.87 
 
     iPF(2a)-lV 
(ng/mg)  
7.53 
(4.126- 9.037) 
5.93 
(4.017- 8.572) 
0.215 6.559 
(5.109- 10.327) 
5.959 
(3.931- 8.572) 
0.15 
    8,12-iso-iPF 
(ng/mg) 
3.125 
(2.490- 5.860) 
3.979 
(2.729- 5.923) 
0.212 4.224 
(2.899- 7.167) 
3.882 
(2.637- 
5.6905) 
0.27 
F2 -isoP Index* -0.025 
(-0.575-0.650) 
-0.000 
(-0.475-0.600) 
0.950 0.100 
(-0.300- 0.650) 
-0.025 
(-0.500- 0.572) 
0.45 
• All continuous variables reported in median ± IQR. Index*- mean of 4 standardized F2-isoPs. 
 
 
 
    Comparison of baseline and follow-up MHO status showed that from 27 individuals 
representing MHO at the baseline, 17 participants progressed into an unhealthy state and 10 
participants remained stable metabolically healthy. Among those who were MUO (n=217) at 
baseline, 12 individuals demonstrated metabolic improvement and moved into a group of 
metabolically healthy and the rest of the group remained unhealthy. The association between 
level of F2 – Isomers and metabolically stable state was not statistically significant with a median 
of F2 -isoP index being of the same value (-0.025ng/mg) among MHO stable and metabolically 
declined groups of individuals (Table4).  
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Table 4 Oxidative status at follow-up among MHO stable and MHO declined 
variable MHO stable (n=10) MHO declined (n=17) p-value 
 Median (IQR) Median (IQR)  
     iPF(2a)-lll 
 (ng/mg) 
0.183 (0.149 - 0.419) 0.178 (0.148 - 0.310) 0.782 
     2,3-dinor-iPF(2a)-
lll 
 (ng/mg) 
4.156 (2.944 - 7.963) 4.322 (3.550 - 6.3705) 0.744 
     iPF(2a)-lV 
(ng/mg)  
7.1937 (4.221 - 8.554) 7.5345 (4.126- 9.037) 0.706 
    8,12-iso-iPF 
(ng/mg) 
2.853 (2.273 - 8.704) 3.2885 (2.515 - 4.250)  0.860 
F2 -isoP Index* -0.025 (-0.600 - 0.650) -0.025 (-0.550- 0.550) 0.920 
• All continuous variables reported in median ± IQR. Index*- mean of 4 standardized F2-
Isoprostanes. 
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                                                      CHAPTER V 
                                                   DISCUSSION  
5.1 Discussion of Research Question 
       The purpose of the study was to examine whether increased oxidative status can promote a 
transition from metabolically healthy obesity (MHO) into metabolically unhealthy obesity 
(MUO). The increased mass of adipose tissue is characterized by the changed structure of 
adipocytes, including their hypertrophy and hyperplasia that affect the property of adipocytes, 
such as reaction to insulin due to decreased density of receptors for insulin (Fernández-Sánchez 
et al., 2011).  The possibility of adipose tissue to produce certain bioactive molecules, including 
leptin and proinflammatory cytokines, such as IL-6 and tumor necrosis factor-alfa (TNF-α) 
promotes higher oxidative and inflammatory status of this tissue (BouloumiÉ et al.,1999, 
Perwez Hussain and Harris, 2007). This property of adipose tissue advances metabolic 
misbalance, including changed lipid profile and altered glucose metabolism. What contributes 
to a diversity of metabolic state among obese remained not well understood. Several studies 
identified an association between age, gender and MHO status (van Vliet-Ostaptchouk et 
al.,2014). Numerous conducted research provided conflicting data on the effect of lifestyle, diet, or 
behavior on metabolic health (Phillips, 2013).  Some researchers provided evidence about the 
positive effect of physical exercise on metabolic health of the obese population (Phillips et al.,2013, 
Velho et al., 2010). Additionally, it has been shown that MHO population has a more favorable 
inflammatory profile compared to MUO (Phillips, 2013). We hypothesized that F2 -Isoprostanes 
as markers of free radical oxidative stress can become a predictor of deteriorating metabolic  
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health among still metabolically healthy obese individuals. Based on the result of our study, we 
did not identify any statistically significant association between level of F2 -Isoprostanes and 
MUO compared to MHO. Neither did we find any statistically significant difference in F2 -
Isoprostanes association between the population who were MHO stable after five years of 
follow-up and those who progressed from MHO to MUO. The result of our study reflects the 
result of the study conducted by Sjorgen et al. (2005), where no association was found between 
markers of oxidative stress and different metabolic health status among obese men. The result of 
our study can be partially attributed to the small sample of metabolically healthy individuals, 27 
participants at baseline and 22 at follow-up and can be considered as one of the limitations of our 
study. Another explanation for this result can be related to the criteria we used to identify MHO. 
There are a variety of criteria used to define metabolic health among obese and the debates about 
which combination of criteria is more correct are still ongoing (Phillips et al., 2013). The criteria 
we used for MHO1 were very basic and included the absence of hypertension, diabetes and 
healthy HDL-cholesterol level. It is possible to think that this MHO group already had 
underlying metabolic changes that had not been manifested yet in the form of diabetes or 
hypertension. Although criteria for MHO2 were stricter and incorporated HOMA, 
triglycerides/HDL-cholesterol ratio and lower level of fasting glucose, such as 100mg/dl as 
recommended by National Cholesterol Education Program Adult Treatment Panel ΙΙΙ 
(NCEP/ATPΙΙΙ) (Lorenzo et al.,2007), the number of individuals who met these criteria was very 
small for drawing any conclusion about the association between F2 -Isoprostanes level and 
metabolic health of this population.      
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    One of the main findings of the study was the identification of the changeable status of 
metabolic health among the obese population.  After 5years of the follow-up period, some of the 
participants with initially healthy metabolic profile remained healthy and some developed 
metabolic abnormalities. Similarly, the group of obese participants who were metabolically 
unhealthy on the baseline demonstrated a bifurcation with some participants remained 
metabolically unhealthy and some demonstrated an improvement in metabolic health (Figure 1).  
Figure 1. Changes in metabolic status among MHO and MUO populations 
 
 
 
 
5.2 Study strengths and limitations  
    One of the strengths of this study is the utilization of prospective cohort data that 
allowed to see not only an association between variables but to determine a possible  
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causation.  Moreover, it provided an opportunity to see the trend of metabolic changes 
among the obese population over a five-year period. Additionally, this study allowed to 
examine the relationship between four F2 - Isoprostanes isomers and metabolic health of 
the nondiabetic obese population in a multiethnic cohort.  
      One of the limitations of the study was the small sample of the obese population 
(n=244) with a small group of MHO. Also, we did not analyze the changes in the diet, 
exercises, and weight in this initially obese cohort group that could affect the transition 
from one category of metabolic health into another, but it was not the purpose of this 
study. 
5.3 Conclusions and recommendations 
   Based on the result of our study we did not identify any causal relationship between 
free radical oxidative stress and development of metabolic abnormalities among the 
metabolically healthy obese adult population. The difference in the level of oxidative 
stress between MHO and MUO was statistically insignificant and at the same time, both 
groups of obese population demonstrated a higher level of oxidative stress compared to 
non-obese. We can conclude that MHO population has invisible pathological processes 
that in the future can manifest as metabolic abnormalities. Considering this result, we 
recommend including MHO group in all programs targeting obesity that can provide 
benefits to the health of obese population regardless of their metabolic profile. Future 
research is needed to investigate what factors can trigger metabolic changes or prevent 
clinical manifestation of oxidative stress among MHO population.   
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Table 2 Metabolically Healthy and Unhealthy Obesity status at baseline and follow-up. 
 Baseline N= 244 (percent) p-value Follow-up N=241 (percent)  p-value 
 Categorical Variable* 
 
MHO 
N=27 
MUO 
N=217 
 MH 
N=22 
MU 
N=219 
 
Age    0.07   0.5 
        40-49 10 (37.04) 71 (32.72)  9 (40.91) 70 (31.96)  
         50-59 13 (48.15) 69 (31.80)  8 (36.36) 74 (33.79)  
         60-69 4 (14.81) 77 (35.48)  5 (22.73) 75 (34.25)  
Gender   0.9   0.7 
        Male 9 (33.33) 70 (32.26)  8 (36.36) 71 (32.42)  
        Female 18 (66.67) 147 (67.64)  14 (63.64) 148 (67.58)  
Ethnicity   0.05   0.08 
       Hispanic 4 (14.81) 81 (37.33)  3 (13.64) 81 (36.99)  
       Non-Hispanic black 12 (44.44) 60 (27.65)  8 (36.36) 64 (29.22)  
      Non-Hispanic white 11 (40.74) 76 (35.02)  11 (50.00) 74 (33.79)  
Smoking status 
 
  0.76   0.06 
          Never    smoked 12 
(44.4) 
111 
(51.2) 
 10 (45.4) 109 (50.7)  
       Former smoker 12 
(44.4) 
81 
(37.3) 
 8 (36.4) 95 (44.2)  
        Current smoker 3 
(11.2) 
25 
(11.5) 
 4 (18.2) 11 (5.1)  
Hypertension 
N, % 
  N/A   N/A 
           Yes 0 143 
(65.90) 
 0 163 (74.43)  
            No 27 
(100.00) 
74 
(34.10) 
 22 (100.00) 56 (25.57)  
Glucose tolerance 
status 
N, % 
  0.01   < .001 
          NGT 20 
(74.06) 
103 
(47.47) 
 19 (86.36) 82 (37.44)  
          IGT 7 
(25.94) 
114 
(52.53) 
 2 (9.09) 68 (31.05)  
Type 2 diabetes N/A N/A  1 (4.55) 69 (31.51)  
Continuous Variable Median ± 
IQR 
Median ± 
IQR 
 Median ± IQR Median ± 
IQR 
 
BMI 
Kg/m2  
33.08 
(31.23-
36.33) 
34.27 
(31.89- 
37.705) 
0.126 30.29 
(29.02- 36.00) 
 35.45 
(31.99- 38.53) 
0.01 
Fasting Glucose 
(mg/dl) 
98.0 
(91-104) 
102.0 
(95-111) 
N/A 96.0 
(90.0-104.5) 
105.5 
(95.5-121.5) 
N/A 
Insulin sensitivity 1.54  0.85 <.001 1.10 0.51 < .001 
 22   
(SI, x10-4minutes-1/µUml) 
 
(1.28-2.62)  (0.370- 
1.54) 
(0.96-2.50) (0.0-0.98) 
Acute Insulin response 
(microU/ml) 
565.0 
(161.6- 
710.8) 
417.6 
(137.4-
790.4) 
0.552 428.5 
(354.8- 735.8) 
346.2 
(98.00- 847.1) 
0.19 
2-hour Glucose 
(mg/dl) 
116 
(95-141) 
142  
(120-167) 
<.001 108.0 
(89.0-122.5) 
155.5 
(124.5- 213.7) 
< .001 
HDL (mg/dl) 55.0 
 (51.0-57.0) 
40.0  
(33.0-46.5) 
N/A 58.5  
(51.0-65.0) 
43.0 
(35.0-51.0) 
N/A 
Triglycerides 
(mg/dl) 
104.0  
(74.0-183.0) 
139.0  
(90.0-182.0) 
N/A 76.0 
(59.0-127.0) 
124.0 
(86.0-179.0) 
N/A 
Fasting Insulin (uU/ml) 14.0 
 (11.0-21.0) 
19.0  
(14.0-26.0) 
0.005 15.0 
(11.0-18.0) 
23.0 
(16.0-33.0) 
< .001 
• Variables value correspond to each time point. All categorical variables reported in N, %, p-value 
for categorical variables assessed using Chi-square.  All continuous variables reported in median 
± IQR assessed using univariate test, p-value for continuous variables assessed using Wilcoxon 
test. 
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